Hemogenyx Pharmaceuticals : 2020 Annual Report (print version)

1	Hemogenyx Pharmaceuticals plc
Annual Report & Financial Statements for the Year Ended 31 December 2020

H E M O G E N Y X P H A R M A C E U T I C A L S P L C

A N N UA L R E P O R T & F I N A N C I A L S TAT E M E N T S F O R T H E Y E A R E N D E D 3 1 D E C E M B E R 2 0 2 0

2	Hemogenyx Pharmaceuticals plc
Annual Report & Financial Statements for the Year Ended 31 December 2020

C O N T E N T S

Company Information	3
Chairman's Statement	4
Board of Directors and Senior Management	12
Strategic Report	15
Directors' Report	22
Governance Report	28
Directors' Remuneration Report	35
Independent Auditor's Report	42
Consolidated Statement of Comprehensive Income	50
Consolidated Statement of Financial Position	51
Company Statement of Financial Position	52
Consolidated Statement of Changes in Equity	53
Company Statement of Changes in Equity	54
Consolidated Statement of Cash Flows	55
Company Statement of Cash Flows	56
Notes to the Financial Statements	57

Hemogenyx Pharmaceuticals plc	3
Annual Report & Financial Statements for the Year Ended 31 December 2020

C O M PA N Y I N F O R M A T I O N

Directors

Dr Vladislav Sandler (Chief Executive Officer)

Professor Sir Marc Feldmann (Chairman)

Alexis Sandler (Non-Executive Director)

Peter Redmond (Non-Executive Director)

Company Secretary

Andrew Wright

Registered Office

5 Fleet Place

London

EC4M 7RD

Registered Number

08401609 (England and Wales)

Joint Brokers

SP Angel Corporate Finance LLP

Prince Frederick House

35-39 Maddox Street

London

W1S 2PP

Peterhouse Capital Limited

80 Cheapside London EC2V 6EE

Independent Auditor

PKF Littlejohn LLP

Statutory Auditor

15 Westferry Circus

Canary Wharf

London

E14 4HD

UK Solicitors

Cooley (UK) LLP

Dashwood

69 Old Broad Street

London

EC2M 1QS

US Solicitors

Rubin & Rudman LLP

50 Rowes Wharf

Boston

Massachusetts 0211

Principal Bankers

Metro Bank plc

One Southampton Row

London

WC1B 5HA

Registrar

Computershare Investor Services plc The Pavilions

Bridgwater Road Bristol

BS13 8AE

4	Hemogenyx Pharmaceuticals plc
Annual Report & Financial Statements for the Year Ended 31 December 2020

C H A I R M A N ' S S TAT E M E N T

Hemogenyx Pharmaceuticals plc	5
Annual Report & Financial Statements for the Year Ended 31 December 2020

C H A I R M A N ' S S T A T E M E N T

It is my pleasure to report that over the past year there was further significant development for Hemogenyx Pharmaceuticals. The period saw further growth and acceleration of the development of the Company's pipeline. This was marked by the creation of additional technologies and product candidates, strengthened intellectual property protection, partnerships with yet more internationally renowned institutions, and - despite the challenges posed by the coronavirus pandemic - continued material steps toward the important transition from a pre-clinical to a clinical study-stage business.

The Company's principal business is the development of new treatments for serious blood diseases such as blood cancers and severe autoimmune diseases, while also focusing on the multi-billion dollar bone marrow/ hematopoietic stem cell transplant market. Our products address large and growing needs, and could enable a much wider range of patients to be treated than is presently the case since they should be more suitable for patients who are currently deemed unfit for bone marrow transplants or for whom there is a lack of suitable donors.

The Company's subsidiary, Immugenyx LLC, continues work on Advanced Hematopoietic Chimeras - mice with uniquely humanised blood/immune systems - as a platform for creating models of various diseases and for discovering treatments and developing new drugs. The

last year has also seen the establishment of an exciting and flexible new platform technology that may be applied to create treatments for some forms of cancer and also for viruses such as SARS-CoV-2, the virus responsible for COVID-19. As a result, the pipeline has grown to a roster of six product candidates, compared to two when the Company first listed on the London Stock Exchange in 2017. This number is unusual for such a small company as Hemogenyx Pharmaceuticals.

The Company's six product candidates are:

• CDX antibody - a bispecific antibody targeting a majority of forms of relapsed/refractory acute myeloid leukaemia ("R/R AML"), subset of acute lymphoblastic leukaemia ("ALL"), and myelodysplastic syndrome (myelodysplasia or "MDS") - conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation.

• CAR-Tcell therapy - chimeric antigen receptor T-cells that are engineered for use in immunotherapy, also targeting R/R AML and being developed as a potential alternative conditioning regimen for bone marrow transplants.
• Hu-PHECstem cell therapy - Human Post-natalHemogenic Endothelial Cells are a type of cell and associated cell therapy that generate cancer-freehematopoietic stem cells for use in transplants to treat blood disorders.
• Humanised mice - Advanced peripheral blood Hematopoietic Chimera mice are a novel type of humanised mice that serve as a platform technology to model a wide variety of diseases for drug discovery and target validation.
• Undisclosed - the Company's early-stage programme designed for the discovery and validation of novel targets and therapeutic-like molecules for the treatment of Lupus and/or other autoimmune diseases, in collaboration with the global biopharmaceutical company Eli Lilly.
• CBR platform - a recently developed platform whose first application is the programming of immune cells for targeting viral pathogens including SARS-CoV-2 and other existing and yet unknown viruses. A further potential application of the CBR platform is to target malignant cells that cause cancers.